NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results
Summary
NextCure reported second-quarter 2025 results and outlined progress across its oncology pipeline. The company said it will dose the first U.S. patient in the SIM0505 Phase 1 study this quarter and continue advancing LNCB74 in multiple cancers. It also highlighted a strategic partnership with Simcere Zaiming and said it is seeking partners for additional clinical and preclinical assets. NextCure ended the quarter with $35.3 million in cash and expects funding to support operations into mid-2026.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected